|
Generic Name : Ruxolitinib
Trade Name(s):
International- Jakafi. This medication is a kinase inhibitor, prescribed for high-risk myelofibrosis. When it is not to be taken (Contraindications):
When it is to be taken : PO- The starting dose is 20 mg 2 times per day, for patients with platelet count greater than 200 X 109/L. How it should be taken : It comes as a tablet to take by mouth, with or without food. Special Instruction : * Caution should be exercised in patients with history of liver or kidney impairment, patients on dialysis, during pregnancy and breastfeeding. * It may cause dizziness, avoid performing any hazardous activity while taking this medication. * Patient may develop with certain types of infection; discuss with your healthcare provider before taking this medication. * It may reduce platelet counts; avoid injury or bruising. * Monitor complete blood count regularly while taking this medication. Side Effects : Most Frequent - Thrombocytopenia and anemia. Miscellaneous - Bruising, dizziness, headache, urinary tract infection, weight gain, flatulence, herpes zoster. * Avoid excess dosage. Storage Conditions : Store it at room temperature (20° to 25°C). |
![]() Comment & Contribute
![]()
![]() ![]() | ||


